PaxMedica (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

March 22, 2024 09:38:55
  • Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases
  • PaxMedica is focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms
  • The ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%
  • There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself

Researchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more than a 780% increase in the number of autism cases in the United Kingdom. This significant increase is partially due to the deeper understanding and awareness of autism and the number of physicians who can diagnose the condition (https://ibn.fm/o5oTZ).

Autism spectrum disorder (“ASD”) is a developmental disorder affecting how individuals interact with other people, behavior, communication, and learning. This disorder can be diagnosed at any age, but symptoms often appear in the first two years of life. There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself.

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. Anti-purinergic therapies target…

Read More >>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]